Pharma Applauds U.K. Election Outcome But EU Renegotiation Creates Uncertainty
This article was originally published in The Pink Sheet Daily
Government support for the Cancer Drugs Fund and life sciences will continue, but a referendum vote to leave the EU over the next two years would create a need for new pharma regulations and a move from London of the European Medicines Agency.
You may also be interested in...
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.